Legal entity
Every one of those 1 sits in a single category, corporate-law. Pascal Soriot is most often covered alongside AstraZeneca, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 4 original sources each against 2.3 for the same window.
Last mentioned: Aug 3, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, corporate-law. Pascal Soriot is most often covered alongside AstraZeneca, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 4 original sources each against 2.3 for the same window. The 9 average consequence score is above the beat benchmark of 5.5 in the same window. We currently track 1 Legal story that mention Pascal Soriot, all published on August 3, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pascal Soriot. Shared-story counts are live from our verified record — not editorial picks.
The proposed mega-merger would immediately trigger intense antitrust reviews in the US, EU, and UK, testing the limits of Trump-era competition enforcement in the pharmaceutical sector. Significant divestitures and political pushback are likely, with a real risk of deal collapse.
Pascal Soriot is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
